# HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases

Source: https://onco.cc/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/  
OnCo record `paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 140 resected bile duct and gallbladder cancers scored by the rules used in the zanidatamab trial, about one in ten was HER2-positive; every strongly stained tumour had extra gene copies, some weakly stained ones did too, and staining was often patchy.

## Summary

HER2 status was evaluated in 140 consecutive surgically resected biliary tract cancers collected between 2020 and 2025 (87 extrahepatic cholangiocarcinomas and 53 gallbladder carcinomas) using immunohistochemistry and dual chromogenic in situ hybridisation. HER2 expression was scored by gastric cancer criteria and positivity was defined by HERIZON-BTC-01 criteria; selected cases were also analysed with a combined IHC-DISH approach.

HER2 expression was 0 in 72.9%, 1+ in 12.1%, 2+ in 8.6% and 3+ in 6.4% of cases. HER2 positivity was 9.2% in extrahepatic cholangiocarcinoma and 9.4% in gallbladder carcinoma. ERBB2 amplification was consistently identified in all IHC 3+ tumours and in a subset of IHC 2+ and, rarely, 1+ cases; the mean ERBB2/CEP17 ratio was 6.2 in 3+ tumours versus 3.9 in amplified 2+ or 1+ tumours (P = 0.001). Combined analysis confirmed that overexpression and amplification sat in the same tumour cells, and HER2 expression frequently showed intratumoral heterogeneity, often involving less than 50% of tumour cells.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Human Pathology
- Year: 2026
- DOI: 10.1016/j.humpath.2026.106234
- Authors: Angerilli V, Gasparello J, Niero M, et al.
- Findings: IHC 0 in 72.9%, 1+ in 12.1%, 2+ in 8.6%, 3+ in 6.4%; HER2-positive 9.4% of gallbladder and 9.2% of extrahepatic tumours.; All IHC 3+ tumours were amplified; mean ERBB2/CEP17 ratio 6.2 in 3+ versus 3.9 in amplified 2+ or 1+ tumours.; Heterogeneous staining, often under 50% of tumour cells.
- What it means: A direct check of the HERIZON-BTC-01 testing algorithm in routine pathology: IHC 3+ can stand alone, 2+ needs ISH, and the low-level amplification in weakly stained tumours is the group where HER2 drugs are least likely to help.
- Caveats: Resected Italian cases; advanced disease may differ.; Chromogenic rather than fluorescent ISH; consecutive but single-region series.

## Sources

- Angerilli et al., Hum Pathol 2026: HER2 IHC and chromogenic ISH concordance in 140 biliary cancers: https://doi.org/10.1016/j.humpath.2026.106234
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42595189/

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- terms: [FISH / ISH (in situ hybridisation)](https://onco.cc/terms/fish/), [HER2 testing in biliary tract cancer (IHC, ISH and NGS)](https://onco.cc/terms/her2-testing-in-biliary-cancer/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/)
- biomarkers: [HER2 IHC 2+ (equivocal, reflex to ISH)](https://onco.cc/biomarkers/her2-ihc-2-plus/), [HER2 IHC 3+ (HER2-positive by immunohistochemistry)](https://onco.cc/biomarkers/her2-ihc-3-plus/), [HER2 ISH amplified (ERBB2 gene amplification)](https://onco.cc/biomarkers/her2-ish-amplified/)

---
JSON: https://onco.cc/api/v1/entities/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026.json